Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02828020 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,672
- Enrollment target
NCT02828020: Completed Phase 3 study, sponsored by Allergan.
NCT02828020 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 1,672 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (117% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02828020, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,672 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
Primary Outcome
Pain freedom was defined as a reduction in headache severity from moderate/severe at baseline to no pain at 2 hours after the initial dose. Participants were provided with an electronic diary (eDiary) to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing postdose pain severity assessment at or before 2 hours after initial dose.
Interventions
- DRUG Ubrogepant
- DRUG Placebo-matching Ubrogepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,672 participants |
| Start Date | 2016-07-22 |
| Est. Completion | 2017-12-14 |
| Phase | Phase 3 |
What the finished NCT02828020 record still lists
NCT02828020 is an interventional study that assigns participants to a tested intervention. Its 1,672 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (117% higher).
The record links to 0 conditions, and to 2 interventions - of which Ubrogepant is the first listed.
NCT02828020 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02828020 about?
NCT02828020 is a clinical study titled "Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine". This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
What is the current status of trial NCT02828020?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,672 participants. The study started on 2016-07-22. Estimated completion is 2017-12-14.
What interventions are being tested in trial NCT02828020?
The interventions under investigation include: Ubrogepant (DRUG), Placebo-matching Ubrogepant (DRUG).
Who is sponsoring clinical trial NCT02828020?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02828020's enrollment target sits among peer trials
1,672 136th of 2000 higher than 1,865 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04852887 · 1,670 participants · Phase 3
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- NCT06644625 · 1,665 participants
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
- NCT06376565 · 1,680 participants · NA
Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps
- NCT06034405 · 1,663 participants
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI